An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators

Category	Detail
Condition	Breast Cancer
Key Mechanisms	Extracellular vesicles (EVs) regulate immune checkpoint signaling, promoting immune evasion and resistance to therapy.
Target Population	Patients with breast cancer, particularly those with varying subtypes including triple-negative, luminal, and HER2-positive.
Care Setting	Oncology and immunotherapy clinics

Extracellular vesicles regulate immune checkpoint signaling and drive immune evasion in breast cancer.
EV-associated PD-L1, CTLA-4, and other immunosuppressive cargos promote T-cell dysfunction and resistance to immunotherapy.
Tumor-derived EVs contribute to immunosuppression by impairing T-cell function and facilitating metastatic progression.
Breast cancer heterogeneity affects immune evasion and responses to immunotherapy.
EVs show potential as minimally invasive biomarkers for disease monitoring.

Consider the role of extracellular vesicles in the immune landscape of breast cancer.

Explore therapeutic strategies targeting EV-mediated immune checkpoint regulation.

Utilize EVs as potential biomarkers for monitoring disease progression and treatment response.

Be aware of the potential for EVs to facilitate immune evasion and resistance to therapies.

Patients with breast cancer, particularly those with immune checkpoint-related challenges.

Focus on the role of EVs in modulating immune responses and their implications for immunotherapy.

Integrate knowledge of EVs in the assessment of immune checkpoint regulation in breast cancer.
Consider the heterogeneity of breast cancer when evaluating treatment responses.

Clinical Scorecard: A Comprehensive Overview of Extracellular Vesicles in Modulating Immune Responses in Breast Cancer, Focusing on Immune Checkpoint Regulators